Literature DB >> 16128925

Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS.

A Nichole Cline1, Julian W Bess, Michael Piatak, Jeffrey D Lifson.   

Abstract

As new assay methods for quantitative reverse transcription-polymerase chain reaction (RT-PCR), such as real time RT-PCR techniques, approach theoretical limits of per reaction sensitivity, further increments in the sensitivity of measurements of viral load can only be achieved by increasing the amount of input RNA per reaction. We describe a robust, convenient, rapid integrated approach for specimen preparation and real time RT-PCR assay for plasma simian immunodeficiency virus (SIV) RNA viral load that provides a threshold sensitivity of 10 copy Eq/ml, and tolerates less than optimally processed specimens. The method provides accurate quantitation of viral load for the SIV virus isolates in common use for non-human primate studies. We demonstrate the utility of the method in sensitively tracking viral load in an animal showing effective control of viral replication to levels below the threshold for quantitation in conventional assays.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16128925     DOI: 10.1111/j.1600-0684.2005.00128.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  253 in total

1.  SIV infection induces accumulation of plasmacytoid dendritic cells in the gut mucosa.

Authors:  R Keith Reeves; Tristan I Evans; Jacqueline Gillis; Fay E Wong; Guobin Kang; Qingsheng Li; R Paul Johnson
Journal:  J Infect Dis       Date:  2012-06-18       Impact factor: 5.226

2.  Ex vivo analysis of SIV-infected cells by flow cytometry.

Authors:  Matthew R Reynolds; Shari M Piaskowski; Kimberly L Weisgrau; Andrea M Weiler; Thomas C Friedrich; Eva G Rakasz
Journal:  Cytometry A       Date:  2010-11       Impact factor: 4.355

3.  Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.

Authors:  Koen K A Van Rompay; Darius Babusis; Zachary Abbott; Yongzhi Geng; Kartika Jayashankar; Jeffrey A Johnson; Jonathan Lipscomb; Walid Heneine; Kristina Abel; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

4.  TCR triggering transcriptionally downregulates CCR5 expression on rhesus macaque CD4(+) T-cells with no measurable effect on susceptibility to SIV infection.

Authors:  Jacob T Minang; Matthew T Trivett; Eugene V Barsov; Gregory Q Del Prete; Charles M Trubey; James A Thomas; Robert J Gorelick; Michael Piatak; David E Ott; Claes Ohlen
Journal:  Virology       Date:  2010-10-28       Impact factor: 3.616

5.  CD16- natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection.

Authors:  R Keith Reeves; Jacqueline Gillis; Fay E Wong; Yi Yu; Michelle Connole; R Paul Johnson
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

6.  Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus.

Authors:  Amitinder Kaur; Hannah B Sanford; Deirdre Garry; Sabine Lang; Sherry A Klumpp; Daisuke Watanabe; Roderick T Bronson; Jeffrey D Lifson; Margherita Rosati; George N Pavlakis; Barbara K Felber; David M Knipe; Ronald C Desrosiers
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

7.  Effect of combination antiretroviral therapy on Chinese rhesus macaques of simian immunodeficiency virus infection.

Authors:  Binhua Ling; Linda Rogers; Ann-Marie Johnson; Michael Piatak; Jeffrey Lifson; Ronald S Veazey
Journal:  AIDS Res Hum Retroviruses       Date:  2013-03-08       Impact factor: 2.205

8.  Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge.

Authors:  Bapi Pahar; Andrew A Lackner; Michael Piatak; Jeffrey D Lifson; Xiaolei Wang; Arpita Das; Binhua Ling; David C Montefiori; Ronald S Veazey
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

9.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

10.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.